Methods for expansion or depletion of t-regulatory cells
AssigneeThe General Hospital Corporation
InventorDenise L. FAUSTMAN
Life of this patent
Estimating the term…
Abstract
The invention features methods of producing compositions enriched in Tregs and methods for treating immunological disorders using these compositions. The invention also features methods for producing compositions enriched in lymphocytes and depleted of Tregs and the use of these compositions in the treatment of proliferative disorders.
Claims90
A method for producing a composition enriched in CD4+CD25hi T regulatory cells (Tregs) comprising contacting in vitro a population of human cells comprising T-lymphocytes obtained from a human blood or bone marrow sample from a patient with a tumor necrosis factor receptor 2 (TNFR2) agonist or an NF-κB activator, thereby producing said composition enriched in Tregs, wherein said Tregs comprise at least 60% of the cells in said composition.
A composition enriched in CD4+CD25hi Tregs, wherein said Tregs comprise at least 60% of the cells in said composition, and wherein said composition comprises at least 5×106 Tregs.
An isolated antibody or antigen-binding fragment thereof that selectively binds to a first epitope of TNFR2, said first epitope comprising positions 48-67 of SEQ ID NO:
- 1, said antibody or antigen-binding fragment thereof having an antagonistic effect on TNFR2 upon binding.
A method for producing a composition enriched in lymphocytes comprising contacting in vitro a population of human cells comprising said lymphocytes obtained from a human blood or bone marrow sample from a patient with a tumor necrosis factor receptor 2 (TNFR2) antagonist or an NF-κB inhibitor that suppresses proliferation of T regulatory cells (Tregs), thereby producing said composition enriched in lymphocytes, wherein said Tregs comprise less than 10% of the cells in said composition.
Dependencies are inferred from the claim text.